A high baseline of intratumoural macrophages and regulatory T cells is associated with better outcomes in patients with non-small cell lung cancer treated with atezolizumab plus tiragolumab, but not with atezolizumab alone.
- Xiangnan Guan
- Ruozhen Hu
- Namrata S. Patil